DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, October 21, 2021
Information
Tags: 
Research, Technology, Medical Devices, FDA, Genetics, Clinical Trials, Biotechnology, Hardware, Health, Science, SYNTAX, Enzyme, Research, Technology, Industry, Genomics, Partnership, EDS, CMR Surgical, View, Director, Leadership, Synthetic biology, Board on Science, Technology, and Economic Policy, Board, CEO, Organic acid, FEI Company, Script, Thermo Fisher Scientific, DNA, Management
Geotags: 
California, Europe, United States, France, KANIA, LONDON, BOSTON
⚠ generated by AI ↴
Organisation: 
DNA SCRIPT
Summary
Key Points: 
  • DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.
  • The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets.
  • Moukheibir brings over 30 years of leadership experience in finance, capital markets and life sciences to DNA Script.
  • DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform, said Thomas Ybert, DNA Script co-founder and CEO.


DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board. With decades of life sciences experience among them, they will play a key role in steering the company’s strategy to deploy its SYNTAX Platform and the EDS technology.

“I firmly believe DNA Script’s EDS technology will have a profound impact on genomics and synthetic biology. The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets. This is an incredibly exciting time for the company,” Kania said. “I have spent my career helping companies grow into life science leaders. I am looking forward to applying my experience and working closely with the Board and the company’s leadership and founders to expand the applications of EDS and grow DNA Script’s DNA-on-demand offerings.”

For over thirty years, Kania has been an influential member of the life sciences industry. Notably, he served as the Chief Executive Officer of FEI Company from 2006 until 2016, when the company was sold to Thermo-Fisher for $4.2 billion. Kania currently advises several startups and serves on a number of boards that span the life sciences and nonprofit sectors.

Moukheibir brings over 30 years of leadership experience in finance, capital markets and life sciences to DNA Script. Most recently, Moukheibir was the chair and CEO of MedDay Pharmaceuticals. She currently serves on the Board of Directors at Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals Inc and Orphazyme. Prior to her current roles, she has held senior management positions at several European biotech companies following an initial career in strategy consulting and investment banking in Boston and London.

Anderson’s career spans over 40 years in regulated diagnostics and life science markets. She co-founded Veracyte in 2008 and served as Chief Executive Officer and Chairman of the Board until June 1, 2021, when she assumed the role of Executive Chairwoman. She led Veracyte’s initial public offering in 2013, spearheaded commercialization of its market-leading products, and was the architect of the company’s vision to become a global enterprise with a growing menu of advanced genomic diagnostics tests and its own distributed instrument platform.

“DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform,” said Thomas Ybert, DNA Script co-founder and CEO. “We now have the first, initial demonstration of the true promise of EDS technology — the ability to produce quick, clean, and high quality synthetic DNA in a benchtop solution to expedite life science discoveries. This is only the beginning; we have barely started. As we continue to expand the company and explore what is possible with EDS technology, the new board members’ partnership and counsel will be invaluable.”

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com

Copyright: 
Copyright Business Wire 2021